The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
 
Laura Quan Man Chow
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Dynavax Technologies; Genentech; Merck; Synthorx; Takeda
Research Funding - ALX Oncology (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Incyte (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Nehal J. Lakhani
Research Funding - Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Formation Biologics (Inst); Forty Seven (Inst); Incyte (Inst); InhibRx (Inst); Jounce Therapeutics (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Keun-Wook Lee
Research Funding - ALX Oncology (Inst); ALX Oncology (Inst); Array BioPharma (Inst); Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Five Prime Therapeutics (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); Green Cross (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Macrogenics (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst)
 
Jeeyun Lee
No Relationships to Disclose
 
Patricia LoRusso
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; Chiltern; CytomX Therapeutics; Five Prime Therapeutics; Genentech; Genmab; Glenmark; Halozyme; Ignyta; Menarini; Novartis; Novella Clinical; Omniox; Roche/Genentech; Takeda
Research Funding - Alexion Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Philip Fanning
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Travel, Accommodations, Expenses - ALX Oncology
 
Yonggang Zhao
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - Alexo Therapeutics; AstraZeneca/MedImmune; Navitor Pharmaceuticals; Sol-Gel
 
Feng Jin
Employment - Theravance
Consulting or Advisory Role - ALX Oncology
 
Hong Wan
Employment - ALX Oncology
Leadership - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology; Pfizer
Patents, Royalties, Other Intellectual Property - patents on targeting CD47-SIRPa
Travel, Accommodations, Expenses - ALX Oncology
 
Jaume Pons
Employment - Alexo Therapeutics
Leadership - Alexo therapeutics
Stock and Other Ownership Interests - Pfizer
Patents, Royalties, Other Intellectual Property - Inventor in many patents owned by Pfizer, Teva and Alexo Therapeutics
 
Sophia Randolph
Employment - ALX Oncology
Stock and Other Ownership Interests - Pfizer
Honoraria - Carrick Therapeutics
Consulting or Advisory Role - Carrick Therapeutics; venBio
 
Wells A. Messersmith
Consulting or Advisory Role - Gilead Sciences; Purdue Pharma; Tanabe Research
Research Funding - Aduro Biotech; Alexo Therapeutics; Immunomedics; OncoMed; Pfizer; Roche/Genentech; Takeda